Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Revance TherapeuticsMadrigal PharmaceuticalsHarmony BiosciencesGeneration BioStoke Therapeutics
SymbolNASDAQ:RVNCNASDAQ:MDGLNASDAQ:HRMYNASDAQ:GBIONASDAQ:STOK
Price Information
Current Price$27.22$124.77$28.15$28.30$30.91
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.71.71.41.81.4
Analysis Score3.53.43.53.53.4
Community Score2.62.82.13.83.0
Dividend Score0.00.00.00.00.0
Ownership Score1.72.50.80.80.8
Earnings & Valuation Score0.60.00.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$37.75$167.60$51.67$40.60$64.33
% Upside from Price Target38.68% upside34.33% upside83.54% upside43.46% upside108.13% upside
Trade Information
Market Cap$1.94 billion$2.00 billion$1.60 billion$1.60 billion$1.13 billion
Beta1.421.19N/AN/A0.63
Average Volume442,049180,346126,336683,567165,817
Sales & Book Value
Annual Revenue$410,000.00N/AN/AN/AN/A
Price / Sales4,739.13N/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.00 per share$27.00 per shareN/AN/A$6.86 per share
Price / Book5.44N/AN/AN/AN/A
Profitability
Net Income$-159,430,000.00$-83,950,000.00N/AN/A$-32,330,000.00
EPS($3.67)($5.45)N/AN/A($1.80)
Trailing P/E RatioN/AN/A0.000.00N/A
Forward P/E RatioN/AN/A24.27N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-5,818.87%N/AN/AN/AN/A
Return on Equity (ROE)-85.72%-47.64%N/AN/A-22.93%
Return on Assets (ROA)-44.85%-43.21%N/AN/A-22.26%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.48%N/A2.04%N/AN/A
Current Ratio7.07%6.84%7.87%31.19%29.02%
Quick Ratio7.01%6.84%7.80%31.19%29.02%
Ownership Information
Institutional Ownership Percentage74.35%74.24%50.17%63.26%N/A
Insider Ownership Percentage4.80%41.89%N/AN/A54.60%
Miscellaneous
Employees4702915010056
Shares Outstanding71.38 million16.03 million56.89 million56.43 million36.66 million
Next Earnings Date5/6/2021 (Estimated)5/6/2021 (Estimated)6/24/2021 (Estimated)6/17/2021 (Estimated)5/21/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down to $34.35Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down to $34.35
americanbankingnews.com - April 12 at 12:36 PM
Birmingham City team news vs Stoke - Bowyer makes two changes and calls-up teen starBirmingham City team news vs Stoke - Bowyer makes two changes and calls-up teen star
birminghammail.co.uk - April 10 at 1:59 PM
Birmingham v Stoke City live - Action from St AndrewsBirmingham v Stoke City live - Action from St Andrew's
stokesentinel.co.uk - April 10 at 1:59 PM
U18s match report: United 6 Stoke 1U18s match report: United 6 Stoke 1
manutd.com - April 10 at 1:59 PM
Birmingham City 2-0 Stoke City: Lukas Jutkiewicz double sees off PottersBirmingham City 2-0 Stoke City: Lukas Jutkiewicz double sees off Potters
bbc.com - April 10 at 1:59 PM
Birmingham 2-0 Stoke City: Lukas Jutkiewicz double fires Blues closer to safetyBirmingham 2-0 Stoke City: Lukas Jutkiewicz double fires Blues closer to safety
skysports.com - April 10 at 1:59 PM
Michael ONeill wants throw-in rule change after Stoke City put on other foot at BirminghamMichael O'Neill wants throw-in rule change after Stoke City put on other foot at Birmingham
stokesentinel.co.uk - April 10 at 1:59 PM
Oversold Conditions For Stoke Therapeutics (STOK)Oversold Conditions For Stoke Therapeutics (STOK)
nasdaq.com - April 6 at 5:47 PM
Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United KingdomStoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom
finance.yahoo.com - March 30 at 7:58 AM
Stoke Therapeutics (NASDAQ:STOK)  Shares Down 3.6% Stoke Therapeutics (NASDAQ:STOK) Shares Down 3.6%
americanbankingnews.com - March 26 at 12:05 PM
Stoke Therapeutics (NASDAQ:STOK) Sees Strong Trading VolumeStoke Therapeutics (NASDAQ:STOK) Sees Strong Trading Volume
americanbankingnews.com - March 25 at 11:19 AM
Stoke Therapeutics to Present at Upcoming Investor ConferencesStoke Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - March 24 at 7:58 AM
Were Not Worried About Stoke Therapeutics (NASDAQ:STOK) Cash BurnWe're Not Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn
finance.yahoo.com - March 15 at 4:37 PM
Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business UpdatesStoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates
finance.yahoo.com - March 9 at 8:20 AM
MRSN Mar 2021 17.500 putMRSN Mar 2021 17.500 put
uk.finance.yahoo.com - March 8 at 9:40 AM
Stoke Therapeutics Inc (STOK) CFO Stephen J Tulipano Sold $1.8 million of SharesStoke Therapeutics Inc (STOK) CFO Stephen J Tulipano Sold $1.8 million of Shares
finance.yahoo.com - February 24 at 8:46 PM
Mersana Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceMersana Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 9:19 AM
Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated MilestonesMersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones
finance.yahoo.com - January 5 at 1:13 PM
MRSN May 2021 17.500 putMRSN May 2021 17.500 put
uk.finance.yahoo.com - January 1 at 3:35 AM
MRSN Jan 2021 12.500 putMRSN Jan 2021 12.500 put
uk.finance.yahoo.com - December 31 at 10:08 PM
MRSN Jan 2021 22.500 putMRSN Jan 2021 22.500 put
uk.finance.yahoo.com - December 31 at 10:08 PM
STOK Jan 2021 50.000 putSTOK Jan 2021 50.000 put
au.finance.yahoo.com - December 29 at 12:38 AM
STOK Feb 2021 65.000 callSTOK Feb 2021 65.000 call
au.finance.yahoo.com - December 28 at 2:33 PM
STOK Jan 2021 30.000 callSTOK Jan 2021 30.000 call
au.finance.yahoo.com - December 27 at 10:16 PM
STOK Feb 2021 20.000 callSTOK Feb 2021 20.000 call
au.finance.yahoo.com - December 27 at 10:16 PM
DateCompanyBrokerageAction
4/14/2021Revance TherapeuticsNeedham & Company LLCReiterated Rating
3/1/2021Revance TherapeuticsHC WainwrightBoost Price Target
2/23/2021Revance TherapeuticsMizuhoBoost Price Target
10/26/2020Revance TherapeuticsBarclaysBoost Price Target
4/16/2020Revance TherapeuticsStifel NicolausLower Price Target
3/27/2020Revance TherapeuticsWilliam BlairReiterated Rating
3/22/2020Revance TherapeuticsThe Goldman Sachs GroupDowngrade
2/25/2020Revance TherapeuticsPiper SandlerBoost Price Target
3/4/2021Madrigal PharmaceuticalsChardan CapitalBoost Price Target
3/2/2021Madrigal PharmaceuticalsOppenheimerLower Price Target
11/23/2020Madrigal PharmaceuticalsEvercore ISIReiterated Rating
11/12/2020Madrigal PharmaceuticalsCanaccord GenuityLower Price Target
11/6/2020Madrigal PharmaceuticalsBMO Capital MarketsBoost Price Target
5/22/2020Madrigal PharmaceuticalsB. RileyBoost Price Target
3/5/2020Madrigal PharmaceuticalsCitigroupLower Price Target
9/14/2020Harmony BiosciencesJefferies Financial GroupInitiated Coverage
3/22/2021Generation BioJPMorgan Chase & Co.Boost Price Target
7/7/2020Generation BioWedbushInitiated Coverage
7/7/2020Generation BioCowenInitiated Coverage
3/16/2021Stoke TherapeuticsCredit Suisse GroupBoost Price Target
11/13/2020Stoke TherapeuticsBTIG ResearchBoost Price Target
10/23/2020Stoke TherapeuticsCantor FitzgeraldInitiated Coverage
(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.